Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.700
+0.010 (0.59%)
At close: Sep 17, 2026, 4:00 PM EDT
1.730
+0.030 (1.76%)
Pre-market: Sep 18, 2026, 4:00 AM EDT
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
$35,714
Profits / Employee
-$2,281,500
Market Cap
296.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enanta Pharmaceuticals | 120 |
| Ocugen | 116 |
| Orchestra BioMed Holdings | 86 |
| Century Therapeutics | 78 |
| Lexeo Therapeutics | 63 |
| X4 Pharmaceuticals | 45 |
| Compass Therapeutics | 39 |
| DiaMedica Therapeutics | 35 |
PALI News
- 1 day ago - Palisade Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 1 day ago - Palisade Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 14 days ago - Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Palisade Bio reports Q2 EPS (22c), consensus (5c) - TheFly
- 5 weeks ago - Palisade Bio Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Palisade Bio Earnings release: Q2 2026 - Filings
- 6 weeks ago - Palisade Bio Slides: Corporate presentation - Filings
- 1 month ago - Palisade Bio initiated with an Outperform at Oppenheimer - TheFly